Xilio Therapeutics, Inc. Stock Price, News & Analysis

Welcome to our dedicated page for Xilio Therapeutics news (Ticker: XLO), a resource for investors and traders seeking the latest updates and insights on Xilio Therapeutics stock.

Xilio Therapeutics, Inc. (Nasdaq: XLO) is a clinical-stage biotechnology company developing tumor-activated, or masked, immuno-oncology therapies for people living with cancer. The XLO news feed on Stock Titan aggregates company-issued press releases and related coverage so readers can follow how Xilio’s pipeline, collaborations and financial position evolve over time.

News about Xilio frequently centers on clinical and preclinical data from its key programs. These include vilastobart, an investigational tumor-activated, Fc-enhanced anti-CTLA-4 antibody being studied in combination with atezolizumab in advanced solid tumors and microsatellite stable metastatic colorectal cancer, and efarindodekin alfa (XTX301), a tumor-activated IL-12 in a Phase 1/2 trial for advanced solid tumors. The company also reports on progress for XTX501, a bispecific PD-1 / masked IL-2 molecule in IND-enabling studies, and multiple masked T cell engager programs targeting tumor-associated antigens such as PSMA, CLDN18.2 and STEAP1.

Investors can use this page to track Xilio’s announcements about clinical trial milestones, data presentations at scientific meetings like the Society for Immunotherapy of Cancer (SITC) and the American Society of Clinical Oncology (ASCO), and updates on collaborations with partners including Gilead, Roche and AbbVie. The feed also captures corporate developments such as financings, warrant exercises, cash runway guidance, stock option plans and board or leadership changes disclosed in press releases and related SEC filings.

By reviewing the XLO news stream, readers gain a consolidated view of how Xilio’s masked immunotherapy platform is progressing through research and development, how external partners are engaging with its programs, and how the company is addressing Nasdaq listing requirements and capital needs as it advances its oncology pipeline.